TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02152085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow pulse
Description: Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wide pulse
Description: Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
Study: NCT02214966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Ramipril, fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Ramipril, fixed dose combination tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat, high caloric meal
Study: NCT02953340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Subcutaneous injection administered on Day 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 IV infusion administered on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 IV infusion administered on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m\^2 IV infusion administered on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m\^2 IV infusion administered on Day 1 of each cycle
Study: NCT04623684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]
Description: 1 drop (6-7 μL) for 3 doses, 5 minutes' intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]
Description: 1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
Study: NCT03234387

Intervention type: OTHER
Intervention: No intervention - only assessments.
Description: No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.

Intervention type: OTHER
Intervention: No intervention - only assessments.
Description: No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.

Intervention type: OTHER
Intervention: No intervention - only assessments.
Description: No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
Study: NCT04026724

Intervention type: DRUG
Intervention: Chinese patent medicine
Description: Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
Study: NCT03945526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT04631575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390, PO,single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390, PO,single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390, PO,single-dose
Study: NCT00632099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone
Description: Oral micronized progesterone (up to 400 mg/day), suspended in olive oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT02537886

Intervention type: DEVICE
Intervention: Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)
Description: Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
Study: NCT01397799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391
Description: Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
Study: NCT03413111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified double wire technique
Description: For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
Study: NCT02975895

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrophobic IOL: Vivinex (HOYA)
Description: Patients requiring cataract surgery will be randomized to one of the two types of IOLs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrophilic IOL: INCISE (Bausch+Lomb)
Description: Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
Study: NCT04035447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Symptom Management for Young Adult Cancer Survivors
Description: The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Symptom Management for Young Adult Cancer Survivors
Description: The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
Study: NCT01823042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine+enteral nutrition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Study: NCT04592640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human amniotic mesenchymal stem cells
Description: 1. Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~2. Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).
Study: NCT02690857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Study: NCT04240444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-coated balloon Catheter
Description: All eligible subjects will be assigned randomly to study group or control group, receive PTCA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon Catheter
Description: All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
Study: NCT03804333

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study: NCT01230307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
Study: NCT02767440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families on Track Intervention
Description: Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
Study: NCT01186575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Context-sensitive text messages are sent to men after undergoing circumcision
Study: NCT03045679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RYGB
Description: laparoscopic RYGB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OAGB/MGB
Description: laparoscopic OAGB/MGB
Study: NCT02111161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG (Privigen)
Description: Three doses of 25 g IVIG (250 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Three doses of Saline 0.9% (250 ml)
Study: NCT03172845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: percutaneous coronary intervention with drug-eluting stent implantation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: percutaneous coronary intervention with drug-eluting stent implantation.
Study: NCT04291443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heavy Force (225g)
Description: Orthodontic Force

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Force (25g)
Description: Orthodontic Force
Study: NCT04484298

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reference position patient is put in a 30 degree supine position during 5 minutes
Description: Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nitroglucerin
Description: 0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
Study: NCT03962101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection
Description: Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
Study: NCT03255681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injections into nasojugal folds
Description: A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane
Study: NCT04070742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101
Study: NCT04652323

Intervention type: DRUG
Intervention: Biocompatibility of calcium silicate cements
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.

Intervention type: DRUG
Intervention: Biocompatibility of calcium silicate cements
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.

Intervention type: DRUG
Intervention: Biocompatibility of calcium silicate cements
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.

Intervention type: DRUG
Intervention: Biocompatibility of calcium silicate cements
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
Study: NCT03227900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intragastric infusion of lidocain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intragastric infusion of water for injections
Study: NCT02577614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Administration of FEIBA after cardiopulmonary bypass

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of placebo after cardiopulmonary bypass
Study: NCT01399788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrin P Forte
Description: Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single drug references
Description: containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
Study: NCT03255707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye patch
Description: Occluding the better seeing eye for a given number of hours daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dichoptic treatment
Description: dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
Study: NCT00734799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention for PTSD (SIP).
Description: Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress.
Study: NCT03535467

Intervention type: OTHER
Intervention: Caregiver's Burden Inventory
Description: The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.

Intervention type: OTHER
Intervention: Caregiver's Burden Inventory
Description: The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
Study: NCT01594515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: High dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Medium dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 101550
Description: High dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Medium dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Medium dose powder for oral solution
Study: NCT04315181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid Agonist
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedatives
Description: Abuse liability evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sedatives
Description: Abuse liability evaluation.
Study: NCT03213964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FATE-NK100
Description: FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: \>1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting.
Study: NCT00595556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: flexible dosages of 100-500mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00827606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
Study: NCT00794677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.